Related Experiment Video
Updated: Apr 26, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Left atrial appendage occlusion with the WATCHMAN™ for stroke prevention in atrial fibrillation
1Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA.
Insights
Left atrial appendage closure with the WATCHMAN device offers a mechanical stroke prevention strategy for patients with atrial fibrillation (AF). This approach reduces thromboembolic risk, addressing limitations of traditional anticoagulants.
Area of Science:
- Cardiology
- Medical Devices
- Interventional Cardiology
Background:
- Atrial fibrillation (AF) significantly increases stroke and embolism risk.
- Current anticoagulants (warfarin, NOACs) carry bleeding risks and limitations.
- The left atrial appendage (LAA) is a primary source of thrombus in AF patients.
Purpose of the Study:
- To review the rationale, technique, safety, and efficacy of the WATCHMAN device for LAA closure.
- To highlight LAA closure as a mechanical stroke prevention strategy in AF.
- To discuss the WATCHMAN device's role in managing thromboembolic risk.
Main Methods:
- Percutaneous implantation of the WATCHMAN LAA closure device.
- Guidance using echocardiography and fluoroscopy.
- Review of data from two randomized clinical trials.
Main Results:
- Transcatheter LAA occlusion with WATCHMAN is clinically effective for stroke prevention in AF.
- Procedural safety has notably improved with experience.
- The device demonstrated efficacy in high-risk AF patients.
Conclusions:
- LAA closure with the WATCHMAN device is a viable alternative to anticoagulation for stroke prevention in AF.
- The procedure offers a mechanical solution to mitigate thromboembolic events.
- Continued research supports the WATCHMAN device's role in AF management.
Abstract:
Atrial fibrillation (AF) is a major cause of stroke and systemic embolism. Although warfarin and the novel oral anticoagulants reduce thromboembolic risk, they are associated with an ongoing bleeding hazard, in addition to other limitations that deter their use. The left atrial appendage (LAA) appears to be the primary source of thrombus in AF; therefore, LAA closure represents a mechanical strategy for stroke prevention in these patients. The WATCHMAN™ LAA closure device (Boston Scientific, Natick, MA) is a nitinol-framed occluder that is implanted percutaneously under echocardiographic and fluoroscopic guidance. Data from two randomized clinical trials support the clinical efficacy of transcatheter LAA occlusion with the WATCHMAN and demonstrate that procedural safety has improved significantly since initial experience. This article summarizes the rationale, procedural technique, safety, and clinical efficacy of the WATCHMAN device in patients with AF at high risk for thromboembolic events.
